サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：循環腫瘍細胞市場：世界の市場機会分析および産業予測、2020-2030年市場
市場調査レポート
商品コード
1147375

循環腫瘍細胞市場：世界の市場機会分析および産業予測、2020-2030年市場

Circulating Tumor Cell Market: Global Opportunity Analysis and Industry Forecast, 2020-2030 Market
出版日: | 発行: Allied Market Research | ページ情報: 英文 | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
循環腫瘍細胞市場：世界の市場機会分析および産業予測、2020-2030年市場
出版日: 2022年11月03日
発行: Allied Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

循環腫瘍細胞検査は、がん患者さんの血液中の腫瘍細胞を検出し、定量化することができます。

CTCには、上皮性、間葉性、幹細胞性、混合性など、さまざまな生物学的表現型が存在します。これらの細胞は血液中にごく微量に存在し、他の細胞（特に白血球）に比べて圧倒的に数が少ないです。そのため、CTCの検出には、分離・濃縮の段階と、検出の第二段階が必要です。最近のCTC同定装置は、ISET、CellSearch System、CTC-chip、EPISPOTなど、すべてこの2つの段階（分離濃縮と検出）を組み合わせたものです。例えば、RosetteSep装置では、密度法およびネガティブセレクションである免疫学的分離法の2種類の濃縮・分離方法が含まれています。循環腫瘍細胞は、診断前、治療前、治療中、治療後など様々な場面で利用される可能性があり、循環腫瘍細胞（CTC）濃縮・分離製品の開発に携わるプレーヤーに有利な成長機会を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の情勢

  • 市場の定義と範囲
  • 主要な調査結果
    • トップクラスの投資先
    • 主要な成功戦略
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
    • 買い手の交渉力
  • 市況分析／トップ企業ポジショニング
    • 2021年市場シェア分析/トップ企業ポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19インパクト分析

第4章 循環腫瘍細胞市場：技術別

  • 市場概要
    • 市場規模・予測：技術別
  • CTC検出エンリッチメントメソッド
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • CTC直接検出法
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • CTC分析
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第5章 循環腫瘍細胞市場：応用分野別

  • 市場概要
    • 市場規模・予測：アプリケーション別
  • クリニカル／リキッドバイオプシー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
    • リスクアセスメント
      • 市場規模および予測
    • スクリーニングとモニタリング
      • 市場規模と予測
  • 調査
    • 主な市場動向、成長要因、機会など
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
    • がん幹細胞の腫瘍形成研究
      • 市場規模・予測
    • 医薬品/治療法開発
      • 市場規模・予測

第6章 循環腫瘍細胞市場：エンドユーザー別

  • 市場概要
    • 市場規模・予測：エンドユーザー別
  • 病院クリニック
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 研究学術機関
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別
  • 診断センター
    • 主な市場動向、成長要因、機会
    • 市場規模・予測：地域別
    • 市場シェア分析：国別

第7章 循環腫瘍細胞市場：地域別

  • 市場概要
    • 市場規模・予測：地域別
  • 北米
    • 主な市場動向とビジネスチャンス
    • 市場規模・予測：技術別
    • 市場規模・予測：アプリケーション別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
    • 米国の循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • カナダ循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • メキシコの循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
  • 欧州
    • 主要な市場動向と機会
    • 市場規模・予測：テクノロジー別
    • 市場規模・予測：アプリケーション別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
    • フランス循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • ドイツ循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • イタリア循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • スペイン循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • 英国循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • その他欧州の循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
  • アジア太平洋地域
    • 主要な市場動向と機会
    • アジア太平洋地域の市場規模・予測：テクノロジー別
    • アジア太平洋地域の市場規模・予測：アプリケーション別
    • アジア太平洋地域の市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
    • 中国循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • 日本循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • インド循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • 韓国循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • オーストラリア循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • その他アジア太平洋地域の循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
  • LAMEA
    • 主な市場動向と機会
    • 市場規模・予測：テクノロジー別
    • 市場規模・予測：アプリケーション別
    • 市場規模・予測：エンドユーザー別
    • 市場規模・予測：国別
    • ブラジル循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • 南アフリカ循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • サウジアラビアの循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • UAE循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別
    • LAMEAのその他の地域循環腫瘍細胞市場
      • 市場規模及び予測：技術別
      • 市場規模及び予測：アプリケーション別
      • 市場規模及び予測：エンドユーザー別

第8章 企業プロファイル

  • Ikonisys Inc.
  • Greiner Bio-One International GmbH
  • Thermo Fisher Scientific
  • SRI International
  • STEMCELL Technologies
  • Miltenyi Biotec
  • Menarini Silicon Biosystems
  • QIAGEN Hannover（QIAGEN）
  • F. Hoffmann-La Roche Ltd.
  • NanoString Technologies, Inc
目次
Product Code: A11918

Circulating tumor cell testing enables the detection and quantification of tumor cells in the blood of cancer patients. Different biological phenotypes of CTCs exist: epithelial, mesenchymal, stem cell-like or mixed. They are present in blood in very small quantities, vastly outnumbered by other cells, especially white blood cells. As a result, their detection needs a phase of isolation-enrichment and a second phase of detection. All the recent CTC identification devices combine these two steps (isolation-enrichment and detection) such as ISET, CellSearch System, CTC-chip or EPISPOT. Sometimes, different methods are used in the same device for one step: for instance, the RosetteSep device includes 2 methods of enrichment/isolation: by density and by immunologic separation which is a negative selection. A number of potential applications of circulating tumor cells in prediagnosis, pre-treatment, and intra and post-treatment provide lucrative growth opportunities to players involved in the development of circulating tumor cell (CTC) enrichment and isolation products.

Covid-19 Scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the circulating tumour cell market

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact analysis:

Increased demand for efficient diagnostic and screening tests and technological advancements in cancer detection is expected to propel the growth of market for CTCs. Several tumor markers that have been introduced in recent years can be used with companion diagnostics to monitor or diagnose a variety of cancers. High adoption of companion diagnostics in monitoring tumor eradication characteristics of cytotoxic drugs is among the few factors propelling the demand in the market for CTCs. Key stakeholders are constantly engaged in endeavours aimed at developing circulating tumor cells based tests, which can prove helpful in the cancer diagnosis. The circulating tumor cell testing is also a useful tool for the development of preventive medicine for cancer. Circulating tumor cell testing can help understand and asses the mechanism of drug during in-vitro experiment in preclinical studies.

Drivers:

Increase in preference for minimum invasive procedure:

Growing demand for minimally invasive diagnostic procedures is anticipated to propel investments by key stakeholders in this area. Circulating tumor cell based liquid biopsy tests lead to limited trauma and enable rapid recovery owing to their non-invasive nature. Moreover, it enables minimal invasive screening of tumors before opting for complex surgical procedures, such as radiotherapy, chemotherapy, and surgical removal of tumors, thus positively impacting the adoption.

Increase in prevalence rate of cancer:

The growing prevalence of cancer is one of the major reasons behind the growth of circulating tumor cell testing market. According to NIH, National Cancer Institute, cancer is one of the major reasons of death globally. According to an estimation from the National Cancer Institute, in 2018 colorectal cancer is projected to contribute around 8.1% of all new cancer cases with estimated deaths around 50,630, which is 8.3% of all cancer deaths caused in the U.S.As reported by the Cancer Research UK, there were 41,804 new cases of colorectal cancer in 2015 and 16,384 deaths due to colon cancer in the U.K. Increase in genetic disorder, alcohol consumption, smoking and lifestyle changes are the major factor behind the rise in cancer cases and also contributing factor for the growth of the circulating tumor cell market.

Key Market players:

  • In March 2018, Biocept Inc received a patent for its Target Selector assays for molecular analysis to improve the patient diagnosis with cancer in China.
  • In May 2021, Natera, a company involved in non-invasive genetic testing and the analysis of circulating cell-free DNA, to present successful results of Signatera, to monitor colorectal cancer and identify disease recurrence.

Key benefits of the report:

  • This study presents the analytical depiction of the global circulating tumor cell industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global circulating tumor cell market share.
  • The current market is quantitatively analyzed from 2021 to 2030 to highlight the global circulating tumor cell market growth scenario.
  • Porter's five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global circulating tumor cell market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Circulating tumor cell Market research report:

  • What are the leading market players active in the circulating tumor cell market?
  • What the current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that would help in taking further strategic steps?

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Share Analysis/Top Player Positioning
    • 3.4.1. Market Share Analysis/Top Player Positioning 2021
  • 3.5. Market Dynamics
    • 3.5.1. Drivers
    • 3.5.2. Restraints
    • 3.5.3. Opportunities
  • 3.6. COVID-19 Impact Analysis

CHAPTER 4: CIRCULATING TUMOR CELL MARKET, BY TECHNOLOGY

  • 4.1. Market Overview
    • 4.1.1. Market Size and Forecast, By Technology
  • 4.2. CTC Detection Enrichment Method
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CTC Direct Detection Methods
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. CTC Analysis
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: CIRCULATING TUMOR CELL MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1. Market Size and Forecast, By Application
  • 5.2. Clinical/Liquid Biopsy
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.4. Risk Assessment
      • 5.2.4.1. Market Size and Forecast
    • 5.2.4. Screening and Monitoring
      • 5.2.4.1. Market Size and Forecast
  • 5.3. Research
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
    • 5.3.4. Cancer Stem Cell Tumorigenesis Research
      • 5.3.4.1. Market Size and Forecast
    • 5.3.4. Drug/Therapy Development
      • 5.3.4.1. Market Size and Forecast

CHAPTER 6: CIRCULATING TUMOR CELL MARKET, BY END USERS

  • 6.1. Market Overview
    • 6.1.1. Market Size and Forecast, By End Users
  • 6.2. Hospital Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Research Academic Institutes
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Diagnostic Centres
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CIRCULATING TUMOR CELL MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1. Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Technology
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End Users
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Circulating Tumor Cell Market
      • 7.2.6.1. Market Size and Forecast, By Technology
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End Users
    • 7.2.7. Canada Circulating Tumor Cell Market
      • 7.2.7.1. Market Size and Forecast, By Technology
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End Users
    • 7.2.8. Mexico Circulating Tumor Cell Market
      • 7.2.8.1. Market Size and Forecast, By Technology
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End Users
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Technology
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End Users
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Circulating Tumor Cell Market
      • 7.3.6.1. Market Size and Forecast, By Technology
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End Users
    • 7.3.7. Germany Circulating Tumor Cell Market
      • 7.3.7.1. Market Size and Forecast, By Technology
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End Users
    • 7.3.8. Italy Circulating Tumor Cell Market
      • 7.3.8.1. Market Size and Forecast, By Technology
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End Users
    • 7.3.9. Spain Circulating Tumor Cell Market
      • 7.3.9.1. Market Size and Forecast, By Technology
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End Users
    • 7.3.10. UK Circulating Tumor Cell Market
      • 7.3.10.1. Market Size and Forecast, By Technology
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End Users
    • 7.3.11. Rest Of Europe Circulating Tumor Cell Market
      • 7.3.11.1. Market Size and Forecast, By Technology
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End Users
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Technology
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End Users
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Circulating Tumor Cell Market
      • 7.4.6.1. Market Size and Forecast, By Technology
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End Users
    • 7.4.7. Japan Circulating Tumor Cell Market
      • 7.4.7.1. Market Size and Forecast, By Technology
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End Users
    • 7.4.8. India Circulating Tumor Cell Market
      • 7.4.8.1. Market Size and Forecast, By Technology
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End Users
    • 7.4.9. South Korea Circulating Tumor Cell Market
      • 7.4.9.1. Market Size and Forecast, By Technology
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End Users
    • 7.4.10. Australia Circulating Tumor Cell Market
      • 7.4.10.1. Market Size and Forecast, By Technology
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End Users
    • 7.4.11. Rest of Asia Pacific Circulating Tumor Cell Market
      • 7.4.11.1. Market Size and Forecast, By Technology
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End Users
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Technology
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End Users
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Circulating Tumor Cell Market
      • 7.5.6.1. Market Size and Forecast, By Technology
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End Users
    • 7.5.7. South Africa Circulating Tumor Cell Market
      • 7.5.7.1. Market Size and Forecast, By Technology
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End Users
    • 7.5.8. Saudi Arabia Circulating Tumor Cell Market
      • 7.5.8.1. Market Size and Forecast, By Technology
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End Users
    • 7.5.9. UAE Circulating Tumor Cell Market
      • 7.5.9.1. Market Size and Forecast, By Technology
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End Users
    • 7.5.10. Rest of LAMEA Circulating Tumor Cell Market
      • 7.5.10.1. Market Size and Forecast, By Technology
      • 7.5.10.2. Market Size and Forecast, By Application
      • 7.5.10.3. Market Size and Forecast, By End Users

CHAPTER 8: COMPANY PROFILES

  • 8.1. Ikonisys Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Greiner Bio-One International GmbH
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Thermo Fisher Scientific
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. SRI International
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. STEMCELL Technologies
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Miltenyi Biotec
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Menarini Silicon Biosystems
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. QIAGEN Hannover (QIAGEN)
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. F. Hoffmann-La Roche Ltd.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. NanoString Technologies, Inc
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Development